Progabide for refractory partial epilepsy: a controlled add-on trial.
Progabide, an experimental GABA-ergic antiepileptic drug, was given in a placebo-controlled double-blind cross-over trial to 19 adult patients with chronic partial epilepsy refractory to previous high-dose antiepileptic drug therapy. A mean daily dose of 32 mg/kg (range, 16 to 63) of progabide did not significantly change the seizure frequency. In patients with a therapeutic response, progabide led to an increase in the plasma concentration of phenytoin and phenobarbital. Comedication with carbamazepine was associated with a poor response to progabide. Side effects were mild except for a several-fold increase of SGOT and SGPT, which required withdrawal of progabide in one patient. Progabide does not seem to be the drug urgently needed for failures of previous high-dose drug therapy.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000927:Anticonvulsants; D002220:Carbamazepine / Q000097:blood / Q000378:metabolism; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010634:Phenobarbital / Q000097:blood / Q000378:metabolism; D010672:Phenytoin / Q000097:blood / Q000378:metabolism; D011897:Random Allocation; D005680:gamma-Aminobutyric Acid / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use
D000927:Anticonvulsants; D002220:Carbamazepine; C017985:progabide; D005680:gamma-Aminobutyric Acid; D010672:Phenytoin; D010634:Phenobarbital